Compare TSLX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | PGEN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2011 | 2013 |
| Metric | TSLX | PGEN |
|---|---|---|
| Price | $17.78 | $4.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $21.61 | $8.33 |
| AVG Volume (30 Days) | 765.5K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $1.20 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.99 | $1.28 |
| 52 Week High | $25.17 | $5.47 |
| Indicator | TSLX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 48.32 |
| Support Level | $17.25 | $3.97 |
| Resistance Level | $18.65 | $4.40 |
| Average True Range (ATR) | 0.52 | 0.24 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 20.31 | 15.26 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.